Japan's Otsuka And Oncotherapy Science Sign Peptide Vaccine Deal
This article was originally published in PharmAsia News
Executive SummaryKawasaki-based OncoTherapy Science inked a licensing deal with Otsuka Pharmaceuticals. Under the terms of the agreement, OncoTherapy will provide Otsuka exclusive development, manufacturing and marketing rights of its peptide vaccine to treat pancreatic cancer. Oncotherapy will receive an up-front payment and royalties from Otsuka after the drug goes on sale. (Click for more-Japanese language
You may also be interested in...
Pfizer has announced that it does not plan to market its Amsparity adalimumab biosimilar in Europe despite it having been endorsed by the EMA in December and being in line for an imminent approval from the European Commission.
Developers of arthroscopy tubing should take additional steps to reduce the risk of patient cross-contamination, the US FDA recommends in a new draft guidance document.
A revised procedure is in place to temporarily list unlicensed products for use in public health emergencies.